REAX vs TTRX
REAX: A technology-driven, cloud-based residential real estate brokerage that recently expanded its scale and services through the acquisition of RE/MAX. TTRX: Turn Therapeutics is a clinical-stage biotechnology company developing GX-03, a non-systemic topical immunomodulator targeting atopic dermatitis and other inflammatory skin conditions.
Side-by-side fundamentals
| Metric | REAX | TTRX | Edge |
|---|---|---|---|
| Price as of 2026-09-09 close | $20.73 | $13.75 | |
| Market cap as of 2026-09-02 | $520M | $410M | |
| PEG as of 2026-09-02 | -2.37 | n/a | |
| Net margin FY2025, SEC XBRL | -0.4% | n/a | |
| Gross margin FY2025, SEC XBRL | +8.4% | n/a | |
| Operating margin FY2025, SEC XBRL | -0.5% | n/a | |
| ROE FY2025, SEC XBRL | -15.7% | -68.2% | REAX higher |
| ROA FY2025, SEC XBRL | -6.4% | -26.3% | REAX higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.97 | REAX lower |
| Revenue growth (YoY) as of 2026-09-02 | +8.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +69.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.11 | 1.25 | |
| 1-year return as of 2026-09-09 close | +304.1% | n/a |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.